The Alabama Medical Cannabis Commission convened on Thursday for a renewed effort to allocate licenses to companies vying for participation in the state’s burgeoning medical cannabis industry.

The proceedings commenced at 10 a.m. in a fully occupied room. Approximately 20 minutes later, the commission opted to enter an executive session – a closed-door gathering. The open meeting is scheduled to recommence around 1:30 p.m.

Legal counsel for the AMCC, William Webster, clarified that the closed session would involve commissioners receiving details about the license applicants. Subsequently, individual lists of nominees for each license category would be compiled.

Webster emphasized that nominees’ lists would remain undisclosed during the closed session. Deliberations and voting on nominees are slated to take place once the meeting reopens to the public at 1:30 p.m.

Webster outlined the process, stating, “Deliberations will not occur during the executive session. The focus will be on sharing information related to the applicants. Each commissioner will confidentially generate a list of nominations for each category. These nominations will not be revealed during the closed session, and there will be no voting during that time.”

One criticism stemming from the initial round of license awards was the lack of public deliberation; decisions were unveiled following the executive session, which led to concerns about transparency.

Webster indicated that the forthcoming open meeting would solely address applicants who had received nominations.

The executive session was also designated to address three other topics permitted under Alabama’s open meetings law. These topics encompass discussions related to individuals’ general reputation, character, professional competence, and ongoing or potential lawsuits involving the commission.

On June 12, the AMCC awarded licenses to 21 companies from a pool of 90 applicants.

However, only four days later, the AMCC suspended these awards, citing potential inconsistencies in the tabulation of scores that aided in ranking the applicants. Consequently, the licenses were not granted.

In response, seven companies that had been unsuccessful in securing licenses on June 12 filed a lawsuit challenging the commission’s procedures. One licensed company also became a defendant in the case.

The licenses cover a spectrum of roles, including cultivation, processing, transportation, testing, and operating dispensaries. Integrated companies that combine several of these functions are also included.

Prior to the executive session on Thursday morning, Rex Vaughn, a Huntsville farmer, was elected as the chairman, succeeding Dr. Steven Stokes. Vaughn, previously the vice chairman, is affiliated with the Alabama Farmers Federation. Stokes, a radiation oncologist from Dothan, resigned from the chairmanship, as he is a trustee at the University of South Alabama, which contravened the commission’s operating rules.

Vaughn commended Stokes’ contributions and leadership, acknowledging their lasting impact. The AMCC also appointed Sam Blakemore, a pharmacist, as the new vice chair. Blakemore praised Stokes’ character and dignified leadership.

Before the licensing suspension, the AMCC anticipated product availability by late this year or early next year. The range of products encompasses gummies, tablets, capsules, tinctures, patches, oils, and other forms allowed by the legislation.

Qualifying patients with medical cannabis cards will be permitted to purchase these products from authorized dispensaries. The medical applications of these products extend to various conditions, including chronic pain, cancer-induced weight loss and nausea, depression, panic disorder, epilepsy, muscle spasms caused by diseases or spinal cord injuries, and PTSD, among others.

Alabama joins 37 other states that have sanctioned medical marijuana, as indicated by the National Conference of State Legislatures.




Major Corporations Investing in Cannabis

As cannabis legalization continues to spread across the country, major corporations are increasingly taking notice and investing in the industry. In April of 2023, a major beverage company announced a $100 million investment in a cannabis-infused drink startup, signaling the growing trend of large corporations entering the cannabis space.

Weed: Revisiting the captivating series hosted by Dr. Sanjay Gupta

Step into a realm where the vibrant green leaves of a plant hold not just the promise of transformation, but a catalyst for societal change. In the backdrop of a world skeptical yet curious, “Weed,” the mesmerizing series guided by the esteemed Dr. Sanjay Gupta, unfolds its narrative. Beyond its captivating storytelling lies a landmark endeavor that challenged perceptions, stirred conversations, and sparked a revolution in the realm of medical science. With a masterful blend of painstaking research, heartrending narratives, and insights from the brightest minds, this seven-episode odyssey embarks on an unprecedented exploration of medical cannabis. As the series aired, it ignited fervent discussions, captivating both public and critical acclaim. “Weed” was more than a documentary; it was a beacon that illuminated the potential to rewrite medical paradigms and the ways in which cannabis could be harnessed for healing. Its impact rippled through society, reshaping attitudes and inspiring advancements in cannabis research, legislation, and compassionate patient care.

Missouri Division of Cannabis Regulation Initiates Recall of 62,000 Cannabis Products: An In-Depth Look at the Delta Extraction Case and Industry Lessons

The Missouri Division of Cannabis Regulation (DCR) has recently taken a significant step in the cannabis industry by issuing a recall of more than 62,000 cannabis products manufactured by Delta Extraction, LLC. The reason behind this recall lies in the fact that these products were not being compliantly tracked in the statewide track and trace system known as METRC. This failure to adhere to tracking protocols created a situation where the DCR could not verify the origins of these products – whether they were sourced from marijuana cultivated within Missouri and had undergone the necessary testing procedures.

Cannabis Milestone: Vermont’s Thriving Marketplace Surpasses $100 Million in Sales

Vermont’s cannabis marketplace is celebrating its first year of operation, and the results are nothing short of impressive. With projections indicating retail sales for the current fiscal year reaching over $100 million, the state has reaped more than $20 million in additional revenue. This milestone underscores the success of Vermont’s foray into regulated cannabis sales.